Ang-4 inhibitors belong to a class of chemical compounds specifically designed to target and modulate the activity of angiopoietin-4 (Ang-4), a member of the angiopoietin family of proteins. Ang-4 is involved in regulating angiogenesis, the process of forming new blood vessels, and plays a crucial role in vascular development and maintenance. By inhibiting Ang-4, these compounds aim to interfere with its signaling pathways and downstream effects on endothelial cells and blood vessel formation.
The specific mechanisms of action of Ang-4 inhibitors may involve various approaches, such as blocking the interaction between Ang-4 and its receptors on endothelial cells or disrupting Ang-4-mediated angiogenic processes. Some Ang-4 inhibitors may be monoclonal antibodies specifically designed to bind to Ang-4 and prevent its interaction with its target receptors, while others could be small molecules that interfere with Ang-4 signaling. The study of Ang-4 inhibitors has provided valuable insights into the role of Ang-4 in angiogenesis and its potential implications in various physiological and pathological conditions. These inhibitors serve as essential tools for researchers to explore the complex regulatory mechanisms governing blood vessel formation. Continued research in this area may lead to a deeper understanding of Ang-4-related biology and open up new possibilities for drug development and scientific exploration in the context of vascular biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a VEGF inhibitor, may indirectly affect Ang-4 levels by modulating the VEGF pathway, which is closely related to angiopoietin signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K/Akt pathway inhibitor, could influence Ang-4 activity due to the interconnected nature of the PI3K/Akt and angiopoietin signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, potentially impacting Ang-4 expression and angiogenesis. | ||||||
DCC-2036 | 1020172-07-9 | sc-364482 sc-364482A | 10 mg 50 mg | $480.00 $1455.00 | ||
Rebastinib, a Tie2 kinase inhibitor, can indirectly influence Ang-4 activity, as Tie2 is a key receptor in angiopoietin signaling. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
YC-1 inhibits HIF-1α, which is involved in the hypoxic regulation of angiogenesis and may indirectly affect Ang-4 levels. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a PDGF receptor inhibitor, could have implications for Ang-4 due to the role of PDGF in vascular development and disease. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT, a γ-secretase inhibitor, affects the Notch signaling pathway, which is involved in vascular development and may influence Ang-4 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 inhibits the TGF-β pathway, which can indirectly impact Ang-4 expression and angiogenesis. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 targets FGF receptors, potentially affecting Ang-4 levels by influencing pathways related to angiogenesis and vascular development. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, may indirectly modulate Ang-4 activity through its role in cell signaling and angiogenesis. | ||||||